SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Brooks Laboratories’ arm gets USFDA’s nod for Meropenem Injection

22 Aug 2022 Evaluate

Brooks Laboratories’ subsidiary company -- Brooks Steriscience (BSL) has received approval for Meropenem Injection 500mg per vial and 1gram per vial (the product) from the United States Food & Drug Administration (USFDA). The product is generic equivalent to the Merrem Injection of Pfizer Inc.

This approval from USFDA marks Brooks’ foray into the US, which is the largest generic market in the World. Brooks manufactures its carbapenem range of injectables at its dedicated facility at Vadodara, India. The facility is approved by several regulatory agencies, including the European Union, and is equipped to produce a wide range of products meeting global quality standards.

Meropenem Injection is an intravenous beta-lactam antibiotic used to treat various bacterial infections. It is indicated for treating complicated skin and skin structure infections, intra-abdominal infections, and bacterial meningitis to reduce the development of drug-resistant bacteria and maintain the effectiveness of the injection and other antibacterial drugs. Meropenem has an estimated market size of $78 million for the twelve months ending June 2022. In May 2022, BSL also received the marketing authorization for Meropenem injections in the United Kingdom and European Union. Global Penem market is $2.6 billion as on June 2022.

Brooks Laboratories is a pharmaceutical contract research and manufacturing services company.

Brooks Laboratories Share Price

62.50 -2.16 (-3.34%)
22-Apr-2026 10:44 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1653.80
Dr. Reddys Lab 1215.95
Cipla 1228.20
Zydus Lifesciences 927.75
Lupin 2307.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×